Global Vitamin D Therapy Market Size Study & Forecast, by Route of Administration (Oral Route, Parenteral Route), By Purchasing Pattern (OTC Drugs, Prescription Drugs), By Application (Osteoporosis, Rickets, Skin Diseases, Muscle Weakness, Autoimmune Disorders, Other Applications), By Age Group (Children, Adults, Senior Adults), and Regional Analysis, 2023-2030
Global Vitamin D Therapy Market is valued approximately at USD 4.59 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 11.6% over the forecast period 2023-2030. Vitamin D therapy involves to the usage of vitamin D supplements or therapeutic methods to mitigate deficits or oversee health issues related to insufficient amounts of vitamin D. It aims to restore optimal vitamin D levels crucial for bone health, immune function, and overall well-being. Administered through oral supplements, injections, or other forms, vitamin D therapy is prescribed based on individual needs and medical history, often guided by laboratory tests. It is beneficial for populations with limited sun exposure, dietary deficiencies, malabsorption issues, or certain medical conditions. The therapy helps prevent or manage conditions such as osteoporosis, rickets, autoimmune disorders and cardiovascular diseases. Healthcare professionals oversee vitamin D therapy to ensure safe and effective outcomes, emphasizing proper dosage and monitoring to avoid toxicity. The increase in awareness campaigns and initiatives about vitamin D deficiency by the government and manufacturers, rise in incidences of the chronic diseases, and rising consumer preference for preventive healthcare are the most prominent factors that are propelling the market demand across the globe.
In addition, the huge patient pool with sedentary lifestyle and rapidly growing aging population is acting as a catalyzing factor for the market demand at a substantial rate. The aging population is more prone to vitamin D deficiency due to reduced skin synthesis and decreased mobility, increasing the need for vitamin D supplementation and therapy among older adults. According to the World Health Organization (WHO), in 2020, it was expected that aging people around the world accounted for 1 billion, which is projected to reach 1.5 billion by the year 2030 which represents 1 in 6 people are more than 60. Moreover, the rise in technological advancements in formulations, as well as the growing investments in research and development presents various lucrative opportunities over the forecasting years. However, the growing consumption of fortified products and the changes in regulatory scenario are hindering the market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Vitamin D Therapy Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the growing awareness of vitamin D deficiency, extensive research to develop more patient-friendly products with improved efficacy and the rise in healthcare spending. Also, the decreased physical activity, obesity, and lower social status are associated with low vitamin D levels. For instance, a CDC report from January 2022 revealed that 25% of American adults do not engage in sufficient physical activity for maintaining health. Physical inactivity rates vary across states and territories, ranging from 17.7% in Colorado to 49.4% in Puerto Rico. This decline in physical activity heightens the risk of vitamin D deficiency among individuals, potentially fueling the demand for treatment and bolstering market expansion. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The growing awareness regarding vitamin D deficiency and bolstered by supportive government initiatives aimed at implementing treatment plans for addressing vitamin D deficiency are significantly propelling the market demand across the region. Additionally, factors such as significant air pollution levels, sedentary lifestyles, escalating incidence of vitamin D deficiency, unconventional dietary habits, reduced sun exposure, and rising malnutrition levels contribute to the increasing demand for vitamin D deficiency treatment in the region.
Major market players included in this report are:Abbott Laboratories (US)
Sanofi SE (France)
GlaxoSmithKline plc (UK)
Pfizer Inc. (US)
Merck & Co., Inc. (US)
Torrent Pharmaceuticals Ltd. (India)
Novartis International AG (Switzerland)
Alkem Laboratories (India)
Sun Pharmaceutical Industries Ltd. (India)
Cadila Healthcare Ltd (India)
Recent Developments in the Market: In August 2022, Arbro Pharmaceuticals introduced Vkap-D3, a plant-based capsule, in India. With a potency of 60,000 IU of Vitamin D3, Vkap-D3 is involved in a unique hard vegetarian liquid-filled capsule shell made of plant-based HPMC. This novel combination is intended to effectively treat vitamin D deficiencies.
Global Vitamin D Therapy Market Report Scope: Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Route of Administration, Purchasing Pattern, Application, Age Group, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Route of Administration:
Oral Route
Parenteral Route
By Purchasing Pattern:
OTC Drugs
Prescription Drugs
By Application:
Osteoporosis
Rickets
Skin Diseases
Muscle Weakness
Autoimmune Disorders
Other Applications
By Age Group:
Children
Adults
Senior Adults
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa
Companies MentionedAbbott Laboratories (US)
Sanofi SE (France)
GlaxoSmithKline plc (UK)
Pfizer Inc. (US)
Merck & Co., Inc. (US)
Torrent Pharmaceuticals Ltd. (India)
Novartis International AG (Switzerland)
Alkem Laboratories (India)
Sun Pharmaceutical Industries Ltd. (India)
Cadila Healthcare Ltd (India)
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.